GNLX Genelux gets fast track status for Olvi-Vec in ovarian cancer
Nov. 27, 2023 3:22 PM ET Genelux Corporation (GNLX) By: Val Brickates Kennedy, SA News Editor
https://stockcharts.com/h-sc/ui?s=GNLX
Genelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer.
The company is currently conducting a Phase 3 registrational study of the immunotherapy in combination with platinum-based chemotherapy in patients with platinum resistant/refractory ovarian cancer.